BXT.F BIONXT SOLUTIONS INC.
- Market cap
- EUR 23.5M
- P/E
- -
- P/B
- 22.68x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is BXT.F undervalued?
Graham numberThe Graham number of BIONXT SOLUTIONS INC. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
BIONXT SOLUTIONS INC. fundamental analysis
No fundamental analysis for BIONXT SOLUTIONS INC. yet.
BIONXT SOLUTIONS INC. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About BIONXT SOLUTIONS INC.
BioNxt Solutions Inc. engages in research, development, manufacture, and sale of next generation drug formulations and delivery systems in Austria, Germany, and Switzerland. The company provides BNT23001for the treatment of multiple sclerosis and myasthenia gravis; BNT24002 for the treatment of lupus nephritis; BNT24003 for the treatment of rheumatoid arthritis; BNT24004 for longevity and anti-aging; BNT24005 for solid organic transplantation; and BNT24006, an oncology drug …
Full company profileBIONXT SOLUTIONS INC. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
BIONXT SOLUTIONS INC. annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 286K | 297K | 372K | 27.0K | 0.00 | 0.00 |
| Gross Profit | 199K | 196K | 372K | - | - | - |
| Operating Income | -16.3M | -6.04M | -6.39M | -4.57M | -6.05M | -7.49M |
| EBITDA | - | -11.5M | -6.48M | -4.32M | -5.77M | -9.28M |
| Net Income | -20.6M | -12.4M | -7.72M | -5.31M | -7.03M | -10.8M |
| EPS | -0.27 | -0.14 | -0.07 | -0.05 | -0.06 | -0.08 |
| Balance Sheet | ||||||
| Total Assets | 9.73M | 1.61M | 1.27M | 569K | 592K | 1.55M |
| Total Liabilities | 8.06M | 5.74M | 6.55M | 8.43M | 9.96M | 7.80M |
| Shareholders' Equity | 1.67M | -4.13M | -5.28M | -7.86M | -9.37M | -6.25M |
| Cash & Short-term Investments | 1.35M | 136K | 364K | 32.4K | 55.3K | 1.20M |
| Cash Flow | ||||||
| Operating Cash Flow | -12.2M | -6.23M | -5.17M | -3.03M | -5.20M | -2.86M |
| Capital Expenditure | 452K | 3.86K | 201K | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -12.6M | -6.23M | -5.37M | -3.03M | -5.20M | -2.86M |
| Ratios | ||||||
| ROE | -1,236.8% | - | - | - | - | - |
| ROA | -212.2% | -767.5% | -609.3% | -932.9% | -1,187.4% | -697.1% |
| Net Profit Margin | -7,203.2% | -4,160.8% | -2,074.7% | -19,683.2% | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
BIONXT SOLUTIONS INC. dividends
BIONXT SOLUTIONS INC. has not paid dividends in the last 6 fiscal years.
Who owns BIONXT SOLUTIONS INC.
- Insiders 5.33%
- Institutions 0.00%
- Public & others 94.67%
- Shares outstanding 136M
- Free float 129M
BIONXT SOLUTIONS INC. company profile
- Company name
- BIONXT SOLUTIONS INC.
- Ticker
- BXT.F
- ISIN
- CA0909741062
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Fiscal year end
- December
- Address
- 1928 Linden Road, Vancouver, BC, Canada, V6M 1E7
- Phone
- 780-818-6422
- Website
- bionxt.com
About BIONXT SOLUTIONS INC.
BioNxt Solutions Inc. engages in research, development, manufacture, and sale of next generation drug formulations and delivery systems in Austria, Germany, and Switzerland. The company provides BNT23001for the treatment of multiple sclerosis and myasthenia gravis; BNT24002 for the treatment of lupus nephritis; BNT24003 for the treatment of rheumatoid arthritis; BNT24004 for longevity and anti-aging; BNT24005 for solid organic transplantation; and BNT24006, an oncology drug targeting chemotherapy platform and anticancer mTOR inhibitor. It also offers diagnostic and biosensor screening tests; transdermal patches and oral dissolvable formulations; and development of psychedelic medicine to treat mental health-related medical conditions, such as depression, anxiety, addiction, and trauma-related stress disorder. The company was formerly known as XPhyto Therapeutics Corp. and changed its name to BioNxt Solutions Inc. in November 2022. BioNxt Solutions Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.
BIONXT SOLUTIONS INC. management
4- Mr. Hugh A. D. Rogers B.Sc., LL.BCo-Founder, CEO & Director · born 1980
- Mr. Wolfgang ProbstCo-Founder, CFO, Corporate Secretary & Director · born 1981
- Dr. Florian A. SahrHead of Project Management
- Dr. Wolfgang WagnerHead of Research & Development